Literature DB >> 31116161

Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy.

Megan C Duggan1, Kelly Regan-Fendt1, Gonzalo N Olaverria Salavaggione1, John Harrison Howard2, Andrew R Stiff1, Julia Sabella1, Nicholas Latchana2, Joseph Markowitz3, Alejandro Gru4, Susheela Tridandapani1, Ann-Kathrin Eisfeld1, Albert de la Chapelle1, William E Carson3.   

Abstract

Neuroblastoma RAS viral oncogene homolog is a commonly mutated oncogene in melanoma, and therapeutic targeting of neuroblastoma RAS viral oncogene homolog has proven difficult. We characterized the expression and phenotypic functions of five recently discovered splice isoforms of neuroblastoma RAS viral oncogene homolog in melanoma. Canonical neuroblastoma RAS viral oncogene homolog (isoform-1) was expressed to the highest degree and its expression was significantly increased in melanoma metastases compared to primary lesions. Isoform-5 expression in metastases showed a significant, positive correlation with survival and tumours over-expressing isoform-5 had significantly decreased growth in a xenograft model. In contrast, over-expression of any isoform resulted in enhanced proliferation, and invasiveness was increased with over-expression of isoform-1 or isoform-2. Downstream signalling analysis indicated that the isoforms signalled differentially through the mitogen-activated protein kinase and PI3K pathways and A375 cells over-expressing isoform-2 or isoform-5 showed resistance to vemurafenib treatment in vitro. The neuroblastoma RAS viral oncogene homolog isoforms appear to play varying roles in melanoma phenotype and could potentially serve as biomarkers for therapeutic response and disease prognosis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31116161      PMCID: PMC7088457          DOI: 10.1097/CMR.0000000000000623

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  20 in total

Review 1.  Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.

Authors:  Panagiotis A Konstantinopoulos; Michalis V Karamouzis; Athanasios G Papavassiliou
Journal:  Nat Rev Drug Discov       Date:  2007-07       Impact factor: 84.694

2.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

3.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

4.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

5.  NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.

Authors:  Ann-Kathrin Eisfeld; Sebastian Schwind; Kevin W Hoag; Christopher J Walker; Sandya Liyanarachchi; Ravi Patel; Xiaomeng Huang; Joseph Markowitz; Wenrui Duan; Gregory A Otterson; William E Carson; Guido Marcucci; Clara D Bloomfield; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-28       Impact factor: 11.205

6.  Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.

Authors:  Christin E Burd; Wenjin Liu; Minh V Huynh; Meriam A Waqas; James E Gillahan; Kelly S Clark; Kailing Fu; Brit L Martin; William R Jeck; George P Souroullas; David B Darr; Daniel C Zedek; Michael J Miley; Bruce C Baguley; Sharon L Campbell; Norman E Sharpless
Journal:  Cancer Discov       Date:  2014-09-24       Impact factor: 39.397

7.  Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing.

Authors:  Xinping Yang; Jasmin Coulombe-Huntington; Shuli Kang; Gloria M Sheynkman; Tong Hao; Aaron Richardson; Song Sun; Fan Yang; Yun A Shen; Ryan R Murray; Kerstin Spirohn; Bridget E Begg; Miquel Duran-Frigola; Andrew MacWilliams; Samuel J Pevzner; Quan Zhong; Shelly A Trigg; Stanley Tam; Lila Ghamsari; Nidhi Sahni; Song Yi; Maria D Rodriguez; Dawit Balcha; Guihong Tan; Michael Costanzo; Brenda Andrews; Charles Boone; Xianghong J Zhou; Kourosh Salehi-Ashtiani; Benoit Charloteaux; Alyce A Chen; Michael A Calderwood; Patrick Aloy; Frederick P Roth; David E Hill; Lilia M Iakoucheva; Yu Xia; Marc Vidal
Journal:  Cell       Date:  2016-02-11       Impact factor: 41.582

8.  Streaming fragment assignment for real-time analysis of sequencing experiments.

Authors:  Adam Roberts; Lior Pachter
Journal:  Nat Methods       Date:  2012-11-18       Impact factor: 28.547

Review 9.  NRAS mutant melanoma--undrugable?

Authors:  Christian Posch; Susana Ortiz-Urda
Journal:  Oncotarget       Date:  2013-04

10.  Landscape of transcription in human cells.

Authors:  Sarah Djebali; Carrie A Davis; Angelika Merkel; Alex Dobin; Timo Lassmann; Ali Mortazavi; Andrea Tanzer; Julien Lagarde; Wei Lin; Felix Schlesinger; Chenghai Xue; Georgi K Marinov; Jainab Khatun; Brian A Williams; Chris Zaleski; Joel Rozowsky; Maik Röder; Felix Kokocinski; Rehab F Abdelhamid; Tyler Alioto; Igor Antoshechkin; Michael T Baer; Nadav S Bar; Philippe Batut; Kimberly Bell; Ian Bell; Sudipto Chakrabortty; Xian Chen; Jacqueline Chrast; Joao Curado; Thomas Derrien; Jorg Drenkow; Erica Dumais; Jacqueline Dumais; Radha Duttagupta; Emilie Falconnet; Meagan Fastuca; Kata Fejes-Toth; Pedro Ferreira; Sylvain Foissac; Melissa J Fullwood; Hui Gao; David Gonzalez; Assaf Gordon; Harsha Gunawardena; Cedric Howald; Sonali Jha; Rory Johnson; Philipp Kapranov; Brandon King; Colin Kingswood; Oscar J Luo; Eddie Park; Kimberly Persaud; Jonathan B Preall; Paolo Ribeca; Brian Risk; Daniel Robyr; Michael Sammeth; Lorian Schaffer; Lei-Hoon See; Atif Shahab; Jorgen Skancke; Ana Maria Suzuki; Hazuki Takahashi; Hagen Tilgner; Diane Trout; Nathalie Walters; Huaien Wang; John Wrobel; Yanbao Yu; Xiaoan Ruan; Yoshihide Hayashizaki; Jennifer Harrow; Mark Gerstein; Tim Hubbard; Alexandre Reymond; Stylianos E Antonarakis; Gregory Hannon; Morgan C Giddings; Yijun Ruan; Barbara Wold; Piero Carninci; Roderic Guigó; Thomas R Gingeras
Journal:  Nature       Date:  2012-09-06       Impact factor: 49.962

View more
  3 in total

1.  Evidence for interaction of the NLRP3 inflammasome and Bruton's tyrosine kinase in tumor-associated macrophages: implications for myeloid cell production of interleukin-1beta.

Authors:  Brooke Benner; Luke Scarberry; Andrew Stiff; Megan C Duggan; Logan Good; Gabriella Lapurga; Jonathan P Butchar; Susheela Tridandapani; William E Carson
Journal:  Oncoimmunology       Date:  2019-09-05       Impact factor: 8.110

2.  Murine Long Noncoding RNA Morrbid Contributes in the Regulation of NRAS Splicing in Hepatocytes In Vitro.

Authors:  Anna Fefilova; Pavel Melnikov; Tatiana Prikazchikova; Tatiana Abakumova; Ilya Kurochkin; Pavel V Mazin; Rustam Ziganshin; Olga Sergeeva; Timofei S Zatsepin
Journal:  Int J Mol Sci       Date:  2020-08-05       Impact factor: 5.923

Review 3.  Splice variants of RAS-translational significance.

Authors:  Erzsébet Rásó
Journal:  Cancer Metastasis Rev       Date:  2020-08-08       Impact factor: 9.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.